Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17733738 | 1.00 | DRD2 (0.50) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL344546 | 1.00 | DRD2 (0.50) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL343563 | 1.00 | DRD2 (0.50) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL25018554 | 0.94 | BTK (0.56) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL1155174 | 0.90 | BTK (0.55) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL3901032 | 0.90 | BTK (0.55) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL3906349 | 0.90 | BTK (0.55) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL3903151 | 0.90 | BTK (0.55) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL19156343 | 0.90 | BTK (0.55) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL6510047 | 0.90 | BTK (0.55) | DRD2BTKEPHX1KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695237-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| EP-4688742-A1 | CYCLOHEXYL OR HETEROCYCLOALKYL BETA-HYDROXY ALKYL AMINES FOR USE IN THE TREATMENT OF HYPERGLYCAEMIA AND DISORDERS CHARACTERISED BY HYPERGLYCAEMIA | Atrogi AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4608810-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS | Septerna, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| WO-2024213625-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024200768-A1 | CYCLOHEXYL OR HETEROCYCLOALKYL BETA-HYDROXY ALKYL AMINES FOR USE IN THE TREATMENT OF HYPERGLYCAEMIA AND DISORDERS CHARACTERISED BY HYPERGLYCAEMIA | ATROGI AB (SE) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024179393-A1 | SULFOXIMINE COMPOUNDS AND APPLICATION THEREOF AS LRRK2 PROTEIN KINASE INHIBITORS | 科辉智药(深圳)新药研究中心有限公司 | 2024-09-06 | — | — | WO | disclosed |
| WO-2024091498-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS | SEPTERNA, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | Halia Therapeutics, Inc. (US) | 2023-02-14 | — | — | US | disclosed |
| CN-1242993-C | Heterocycle derivatives and drugs | NIPPON SHINYAKU CO LTD (JP) | 2006-02-22 | — | — | CN | disclosed |
| WO-2005095357-A2 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-13 | — | — | WO | disclosed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | disclosed |
| US-6794389-B2 | Quinazoline derivatives and drugs | NIPPON SHINYAKU CO., LTD. (JP) | 2004-09-21 | — | — | US | disclosed |
| EP-1432693-A2 | MCH RECEPTOR ANTAGONISTS | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-06-30 | — | — | EP | disclosed |
| US-20030119855-A1 | Heterocycle derivatives and drugs | NIPPON SHINYAKU CO., LTD. (JP) | 2003-06-26 | — | — | US | disclosed |
| CN-1422255-A | Heterocycle derivatives and drugs | NIPPON SHINYAKU CO LTD (JP) | 2003-06-04 | — | — | CN | disclosed |
| EP-1306372-A1 | HETEROCYCLE DERIVATIVES AND DRUGS | Nippon Shinyaku Co., Ltd. (JP) | 2003-05-02 | — | — | EP | disclosed |
| WO-2003028641-A2 | MCH RECEPTOR ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119855-A1 | Heterocycle derivatives and drugs | OPRL1, OPRK1, OPRD1 | DRD2 382/4885BTK 673/4885EPHX1 1204/4885 |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PRKAR2B | DRD2 1561/4885BTK 352/4885EPHX1 3742/4885 |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | DRD2 41/4885BTK 1667/4885EPHX1 504/4885 |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | LRRK2, SNCA, PRKAR2B | DRD2 1561/4885BTK 352/4885EPHX1 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.